Intravitreal bevacizumab (avastin) combined with vitrectomy for recurrences of proliferative vitreoretinopathy in Von Hippel-Lindau disease

Acta Ophthalmol. 2012 Mar;90(2):e157-8. doi: 10.1111/j.1755-3768.2011.02108.x. Epub 2011 Jun 8.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Angiogenesis Inhibitors / therapeutic use*
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Bevacizumab
  • Combined Modality Therapy
  • Female
  • Humans
  • Intravitreal Injections
  • Male
  • Recurrence
  • Treatment Outcome
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Vitrectomy*
  • Vitreoretinopathy, Proliferative / diagnosis
  • Vitreoretinopathy, Proliferative / etiology
  • Vitreoretinopathy, Proliferative / therapy*
  • von Hippel-Lindau Disease / complications*
  • von Hippel-Lindau Disease / diagnosis

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Bevacizumab